Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Learn which Dividend Aristocrats ETF charges the lowest fees and how that can impact long-term performance. We compare expense ratios and help you choose smarter.
27,457 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Palantir stock has fallen from its all-time high, but a fall doesn’t mean a free pass to buy. This guide breaks down ...
A GOP lawmaker is proposing language to widen a congressional stock ban bill to cover prediction markets like Kalshi ...
As of Jun 26, 2026, major tokens face renewed pressure with ETH and XRP testing critical supports while ADA and BNB s...
Google moves forward on a Pentagon AI deal while roughly six hundred staffers sign a protest letter. The era of stron...
Pi Network’s PI surged as the top performer among the top-100, up around 40% for the week. Yet traders eye rising exc...
A rural Louisiana parish is undergoing a dramatic shift as Meta nears completion of a sprawling data center. The proj...
A new move from Google signals a shift in AI compute. This could tilt the balance away from Nvidia in certain cloud a...
A broad crypto rout drags BitMine Immersion Technologies and Strategy lower as Ethereum tumbles about 7% in 24 hours....
California voters will decide this November on a one-time 5% wealth tax aimed at billionaires to shore up Medicaid fu...
A stock that falls 30% in 2026 isn’t automatically a loss. This guide shows how to evaluate a growth stock down 2026,...
Li Lu’s Himalaya Capital places a near alarmingly large bet on Alphabet, powering a dramatic year for the fund and re...